Wedbush initiated coverage of Jade Biosciences (JBIO) with an Outperform rating and $17 price target The company will focus efforts exclusively on its autoimmune pipeline which includes JADE-001, a monoclonal antibody targeting the APRIL pathway in IgA nephropathy, the analyst tells investors in a research note. Wedbush sees potential for further differentiation with JADE-001 versus other anti-APRIL agents. Additionally, with earlier entrants offering target validation, this is a relatively de-risked approach, contends the firm.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue